Format

Send to

Choose Destination
BMC Cancer. 2018 Apr 3;18(1):379. doi: 10.1186/s12885-018-4267-z.

Improved effects of honokiol on temozolomide-induced autophagy and apoptosis of drug-sensitive and -tolerant glioma cells.

Author information

1
Department of Neurosurgery, Chi-Mei Medical Center, Tainan, Taiwan.
2
Graduate Institute of Medical Sciences, College of Medicine and Comprehensive Cancer Center, Taipei Medical University, 250 Wu-Hsing St., Taipei, 110, Taiwan.
3
Cellular Physiology and Molecular Image Research Center and Department of Anesthesiology, Wan-Fang Hospital, Taipei Medical University, Taipei, Taiwan.
4
Department of Neurosurgery, Shuang Ho Hospital, Taipei Medical University, Taipei, Taiwan.
5
Graduate Institute of Neural Regenerative Medicine, Taipei Medical University, Taipei, Taiwan.
6
Anesthesiology and Health Policy Research Center and Department of Anesthesiology, Taipei Medical University Hospital, Taipei Medical University, Taipei, Taiwan.
7
Institute of Toxicology, College of Medicine, National Taiwan University, Taipei, Taiwan.
8
Graduate Institute of Medical Sciences, College of Medicine and Comprehensive Cancer Center, Taipei Medical University, 250 Wu-Hsing St., Taipei, 110, Taiwan. rmchen@tmu.edu.tw.
9
Cellular Physiology and Molecular Image Research Center and Department of Anesthesiology, Wan-Fang Hospital, Taipei Medical University, Taipei, Taiwan. rmchen@tmu.edu.tw.
10
Anesthesiology and Health Policy Research Center and Department of Anesthesiology, Taipei Medical University Hospital, Taipei Medical University, Taipei, Taiwan. rmchen@tmu.edu.tw.

Abstract

BACKGROUND:

Temozolomide (TMZ)-induced side effects and drug tolerance to human gliomas are still challenging issues now. Our previous studies showed that honokiol, a major bioactive constituent of Magnolia officinalis (Houpo), is safe for normal brain cells and can kill human glioma cells. This study was further aimed to evaluate the improved effects of honokiol and TMZ on drug-sensitive and -resistant glioma cells and the possible mechanisms.

METHODS:

TMZ-sensitive human U87-MG and murine GL261 glioma cells and TMZ-resistant human U87-MR-R9 glioma cells were exposed to honokiol and TMZ, and cell viability and LC50 of honokiol were assayed. To determine the death mechanisms, caspase-3 activity, DNA fragmentation, apoptotic cells, necrotic cells, cell cycle, and autophagic cells. The glioma cells were pretreated with 3-methyladenine (3-MA) and chloroquine (CLQ), two inhibitors of autophagy, and then exposed to honokiol or TMZ.

RESULTS:

Exposure of human U87-MG glioma cells to honokiol caused cell death and significantly enhanced TMZ-induced insults. As to the mechanism, combined treatment of human U87-MG cells with honokiol and TMZ induced greater caspase-3 activation, DNA fragmentation, cell apoptosis, and cell-cycle arrest at the G1 phase but did not affect cell necrosis. The improved effects of honokiol on TMZ-induced cell insults were further verified in mouse GL261 glioma cells. Moreover, exposure of drug-tolerant human U87-MG-R9 cells to honokiol induced autophagy and consequent apoptosis. Pretreatments with 3-MA and CLQ caused significant attenuations in honokiol- and TMZ-induced cell autophagy and apoptosis in human TMZ-sensitive and -tolerant glioma cells.

CONCLUSIONS:

Taken together, this study demonstrated the improved effects of honokiol with TMZ on autophagy and subsequent apoptosis of drug-sensitive and -tolerant glioma cells. Thus, honokiol has the potential to be a drug candidate for treating human gliomas.

KEYWORDS:

Autophagy and apoptosis; Drug tolerance; Glioma cells; Honokiol; Temozolomide

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center